Last reviewed · How we verify
ENJAYMO (SUTIMLIMAB-JOME)
ENJAYMO (generic name: SUTIMLIMAB-JOME) is a Classical Complement Pathway Inhibitor [EPC] drug developed by RECORDATI RARE DISEASES, INC.. It is currently FDA-approved for Cold autoimmune hemolytic anemia.
ENJAYMO is a monoclonal antibody that inhibits the complement C1s subcomponent. It works as a complement C1s inhibitor, classified as an inhibitor drug.
At a glance
| Generic name | SUTIMLIMAB-JOME |
|---|---|
| Sponsor | RECORDATI RARE DISEASES, INC. |
| Drug class | Classical Complement Pathway Inhibitor [EPC] |
| Target | Complement C1s subcomponent |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Cold autoimmune hemolytic anemia
Common side effects
- Headache
- Hypertension
- Rhinitis
- Acrocyanosis
- Raynaud's phenomenon
- Urinary tract infection
- Respiratory tract infection
- Bacterial infection
- Nasopharyngitis
- Viral infection
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENJAYMO CI brief — competitive landscape report
- ENJAYMO updates RSS · CI watch RSS
- RECORDATI RARE DISEASES, INC. portfolio CI
Frequently asked questions about ENJAYMO
What is ENJAYMO?
ENJAYMO (SUTIMLIMAB-JOME) is a Classical Complement Pathway Inhibitor [EPC] drug developed by RECORDATI RARE DISEASES, INC., indicated for Cold autoimmune hemolytic anemia.
What is ENJAYMO used for?
ENJAYMO is indicated for Cold autoimmune hemolytic anemia.
Who makes ENJAYMO?
ENJAYMO is developed and marketed by RECORDATI RARE DISEASES, INC. (see full RECORDATI RARE DISEASES, INC. pipeline at /company/recordati-rare-diseases-inc).
What is the generic name of ENJAYMO?
SUTIMLIMAB-JOME is the generic (nonproprietary) name of ENJAYMO.
What drug class is ENJAYMO in?
ENJAYMO belongs to the Classical Complement Pathway Inhibitor [EPC] class. See all Classical Complement Pathway Inhibitor [EPC] drugs at /class/classical-complement-pathway-inhibitor-epc.
What development phase is ENJAYMO in?
ENJAYMO is FDA-approved (marketed).
What are the side effects of ENJAYMO?
Common side effects of ENJAYMO include Headache, Hypertension, Rhinitis, Acrocyanosis, Raynaud's phenomenon, Urinary tract infection.
What does ENJAYMO target?
ENJAYMO targets Complement C1s subcomponent and is a Classical Complement Pathway Inhibitor [EPC].
Related
- Drug class: All Classical Complement Pathway Inhibitor [EPC] drugs
- Target: All drugs targeting Complement C1s subcomponent
- Manufacturer: RECORDATI RARE DISEASES, INC. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Cold autoimmune hemolytic anemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing